Valeant Pharmaceuticals Intl
13F holders, Q3 2024 (September 30)1holders
0new positions
0sold out
$8.16avg. 13F price*
At the end of Q3 2024, 1 institutions reported holding Valeant Pharmaceuticals Intl in their 13F filings, unchanged from Q2 2024. 0 opened new positions and 0 sold out. The largest holder was Bruce & Co., Inc. ($3.7M).
- Company
- Valeant Pharmaceuticals Intl
- Filed as
- Bausch Health (Q3 2024)
- CUSIP
- 91911K102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 100,000 shares sold, net −100,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Bruce & Co., Inc. | 1.07% | Reduce -18.2% | 450,000 | $3.7M |
"% of holder's portfolio" is VALEANT PHARMACEUTICALS INTL's weight in each manager's 13F, not the share of Valeant Pharmaceuticals Intl the manager owns.